Oncology-New York最新文献_第3页

Diagnosing and Treating Blastic Plasmacytoid Dendritic Cell Neoplasm in a Resource-Limited Setting. 在资源有限的环境中诊断和治疗痉挛性浆细胞树突状细胞肿瘤。

4区医学

Oncology-New York Pub Date : 2024-03-01 DOI: 10.46883/2024.25921014

Fiza Khan, Foorquan Hashmi, Nerses Ghahramanyan, Elen Baloyan, Gevorg Tamamyan, Marina Konopleva, Naveen Pemmaraju, Astghik Voskanyan

引用次数: 0

Extreme Case of Surgical Port Metastasis in Ovarian Cancer. 卵巢癌手术孔转移的极端病例。

4区医学

Oncology-New York Pub Date : 2024-03-01 DOI: 10.46883/2024.25921015

Michał Kostrzanowski, Grzegorz Ziółkowski, Filip Dąbrowski

引用次数: 0

Rising Prices and Lower Medicare Reimbursement Rates Create Outrage Among Clinicians. 价格上涨和医疗保险报销比例降低引起临床医生的愤怒。

4区医学

Oncology-New York Pub Date : 2024-03-01 DOI: 10.46883/2024.Pubmed Id

Nora Janjan Md Mpsa Mba, Patrick J Silva

引用次数: 0

Rising Prices and Lower Medicare Reimbursement Rates Create Outrage Among Clinicians. 价格上涨和医疗保险报销比例降低引起临床医生的愤怒。

4区医学

Oncology-New York Pub Date : 2024-03-01 DOI: 10.46883/2024.25921016

Nora Janjan Md Mpsa Mba, Patrick J Silva

引用次数: 0

Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma. 推动发现和治疗套细胞淋巴瘤二十年。

4区医学

Oncology-New York Pub Date : 2024-02-05 DOI: 10.46883/2024.25921013

Lymphoma Research Foundation Lymphoma Research Foundation

{"title":"Twenty Years of Advancing Discoveries and Treatment of Mantle Cell Lymphoma.","authors":"Lymphoma Research Foundation Lymphoma Research Foundation","doi":"10.46883/2024.25921013","DOIUrl":"10.46883/2024.25921013","url":null,"abstract":"Mantle cell lymphoma (MCL) is an aggressive subtype of non-Hodgkin lymphoma characterized by the t(11;14) chromosomal translocation, which leads to the dysregulation of the cell cycle through overexpression of cyclin D1. Although advances in treatment have improved outcomes, in particular the introduction of Bruton tyrosine kinase inhibitors to the treatment armamentarium and more recently chimeric antigen receptor T-cell therapy, MCL often rapidly develops resistance and has a high rate of relapse. In addition, MCL is clinically heterogeneous. Response to treatment can vary, making it difficult to establish a standard treatment approach. Thus, there remains a significant need for more research on MCL biology, including those molecular mechanisms underpinning treatment response or lack thereof, so that novel agents may be identified and/or the use of existing agents may be optimized. At the Lymphoma Research Foundation's 20th MCL Scientific Consortium and Workshop, researchers gathered to discuss recent developments in both basic scientific and clinical research to continue to develop an understanding of MCL and improve outcomes for patients. This report, which includes a summary of each presentation, reviews the findings presented at the workshop and highlights opportunities, open questions, and areas for future study that would pave the way for a cure for this disease in the coming decades.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 2","pages":"51-67"},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139991790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Building Efficiency and Scaling With a Remote Genetic Counseling Program. 提高远程遗传咨询计划的效率和规模。

4区医学

Oncology-New York Pub Date : 2024-01-09 DOI: 10.46883/2024.25921011

Smita K Rao, L Johnetta Blakely, Kate Small, Stephen Schleicher, Natalie R Dickson Md

{"title":"Building Efficiency and Scaling With a Remote Genetic Counseling Program.","authors":"Smita K Rao, L Johnetta Blakely, Kate Small, Stephen Schleicher, Natalie R Dickson Md","doi":"10.46883/2024.25921011","DOIUrl":"10.46883/2024.25921011","url":null,"abstract":"Purpose A third-party telemedicine (TM) genetic counseling program was initiated at a large community oncology practice spanning 35 clinical sites with 110 clinicians and 97 advanced practice providers throughout Tennessee and Georgia. Patients and Methods Appropriate patients were referred through the electronic health record (EHR) based on current National Comprehensive Cancer Network guidelines. A combination of TM and genetic counseling assistants enhanced convenience, broadened access, and decreased no-show rates. Physician education for mutation-positive screening recommendations was provided through deep integration of dedicated genetic counseling notes in the EHR. Results From 2019 to 2022, the program expanded from 1 to 20 clinics with referrals growing from 195 to 885. An average of 82% of patients completed genetic counseling consultations over TM with more than 70% completing genetic testing. The average was 4 to 6 days from referral to consultation. The no-show rate was maintained at less than 7%. In 2023, this model supported all 35 clinics across the state. Conclusion Our program illustrates how remote genetic counseling programs are an effective choice for scaling genetics care across a large community oncology practice. Deep integration of TM genetic counseling within the EHR helps identify patients who are high risk and improves test adoption, patient keep rate, and turnaround time, helping to achieve better patient outcomes.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 1","pages":"20-25"},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139652146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy. 妇科癌症幸存者的生活经历：在意大利进行的一项调查

4区医学

Oncology-New York Pub Date : 2024-01-09 DOI: 10.46883/2024.25921012

Sonia La Spina, Paolo Scollo, Basilio Pecorino, Valentina Lombardo, Annamaria Motta, Rosa Gioia Calderone, Stefania Calì, Helga Lipari, Giuseppa Scandurra

{"title":"Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy.","authors":"Sonia La Spina, Paolo Scollo, Basilio Pecorino, Valentina Lombardo, Annamaria Motta, Rosa Gioia Calderone, Stefania Calì, Helga Lipari, Giuseppa Scandurra","doi":"10.46883/2024.25921012","DOIUrl":"10.46883/2024.25921012","url":null,"abstract":"Background: The study of health-related quality of life in survivors of gynecologic cancers is becoming increasingly important as 1.5 million survivors of gynecologic cancer in the United States and more are expected due to advances in diagnosis and treatment. This project investigated the perceived needs and lived experiences of survivors of gynecological cancer to help design supportive activities to be implemented in clinical practice.Methods: Patients were recruited in hospitals or through social media and responded to an online survey that was addressed to patients in Italy, specifically in Sicily, Puglia, and Campania. Patients with ovarian, endometrium, or cervix cancer were recruited among women attending Cannizzaro Hospital and Alleanza Contro il Tumore Ovarico (Alliance Against Ovarian Cancer) members.Results: Body image perception was changed in 82.3% of respondents, whereas familial relationships were described as changed by 27.5% of women. In 69.6% of patients, sexual habits were hindered by changes in the body, depression, pain, and awkwardness. Physicians informed patients about sexuality changes related to cancer extensively in 16.7% of cases and briefly in 19.6% of cases. The advice of a clinical sexologist was considered potentially helpful by 31.4% of patients and not potentially helpful by 47.1%, whereas 21.6% of patients had no opinion.Conclusions: Although sexual habits are often changed by cancer, women surviving gynecological cancer rarely seek medical advice in this area. Physicians should be trained to inform patients and to promote referrals to sexologists.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"38 1","pages":"15-19"},"PeriodicalIF":0.0,"publicationDate":"2024-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139652147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Early Access to Electronic Health Records May Influence the Patient Experience. 尽早使用电子病历可能会影响患者体验。

4区医学

Oncology-New York Pub Date : 2023-12-14 DOI: 10.46883/2023.25921010

Mehmet Sitki Copur, Soe Min Tun, Adam J Horn

引用次数: 0

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer. 与晚期胰腺癌患者对全身疗法异常反应相关的基因组预测因子

4区医学

Oncology-New York Pub Date : 2023-12-14 DOI: 10.46883/2023.25921008

Suneel Kamath, Joanna Roopkumar, Ying Ni, Minqian Shen, Pablo Bejarano, Daniela Allende, Arun Nagarajan, Tim Nguyen, Bachar Dergham, Dale Shepard, Marc A Shapiro, Michael J McNamara, Bassam N Estfan, Kanika G Nair, Alok A Khorana

{"title":"Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer.","authors":"Suneel Kamath, Joanna Roopkumar, Ying Ni, Minqian Shen, Pablo Bejarano, Daniela Allende, Arun Nagarajan, Tim Nguyen, Bachar Dergham, Dale Shepard, Marc A Shapiro, Michael J McNamara, Bassam N Estfan, Kanika G Nair, Alok A Khorana","doi":"10.46883/2023.25921008","DOIUrl":"10.46883/2023.25921008","url":null,"abstract":"Introduction: Exceptional response to therapy is rare in patients with advanced pancreatic cancer. This study explored potential genomic differences between typical and exceptional responses that could confer more favorable biology.Methods: We included exceptional responders and controls with advanced pancreatic cancer from Cleveland Clinic from April 2013 to August 2017. Exceptional responders were defined as patients with an overall survival of more than 18 months for metastatic disease and more than 24 months for locally advanced disease. Clinical data were obtained, and next-generation sequencing was performed. Statistical analyses comparing the 2 groups were performed using descriptive statistics, the Kaplan-Meier method, and the log-rank test.Results: The study comprised 4 exceptional responders and 6 controls. Both groups were well balanced in age, sex, race, and treatment regimens. Exceptional responders had significantly fewer nonsynonymous mutations than controls (2.25 vs 5.17; P = .014). A mutation count of less than 3 was associated with significantly better progression-free survival (17.2 vs 2.3 months; P = .002) and overall survival (29.4 vs 4.6 months; P = .013). Tumor mutational burden did not differ between exceptional responders and controls (4.88 vs 5.70 mut/Mb; P = .39).Conclusion: A lower number of nonsynonymous mutations may correlate with exceptional outcomes in patients with pancreatic cancer. These findings should encourage future studies into genomic signatures of exceptional response.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"37 12","pages":"488-495"},"PeriodicalIF":0.0,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review. 达那唑治疗骨髓增生异常综合征：系统综述。

4区医学

Oncology-New York Pub Date : 2023-12-14 DOI: 10.46883/2023.25921009

Sangam Shah, Rukesh Yadav, Abhinav Bhattarai, Sunraj Tharu, Prakash Sharma, Prativa Subedi, Arun Kharel, Pitambar Khanal, Pradeep Khanal Pradeep Khanal Mbbs Md, Sri Kollepara, Krishna Gundabolu

{"title":"Danazol for the Treatment of Myelodysplastic Syndromes: A Systematic Review.","authors":"Sangam Shah, Rukesh Yadav, Abhinav Bhattarai, Sunraj Tharu, Prakash Sharma, Prativa Subedi, Arun Kharel, Pitambar Khanal, Pradeep Khanal Pradeep Khanal Mbbs Md, Sri Kollepara, Krishna Gundabolu","doi":"10.46883/2023.25921009","DOIUrl":"10.46883/2023.25921009","url":null,"abstract":"Purpose To study the potential utility of danazol for treating patients with myelodysplastic syndromes, with a focus on efficacy and adverse effects (AEs). Methods MEDLINE In-Process & Other Non-Indexed Citations, MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus were searched for relevant publications from inception June 1, 1950, until June 28, 2022. The studies were screened by title and abstract, followed by full-text screening. The quality of the included studies was assessed via a prespecified set of questionnaires. Data on the efficacy measures and adverse outcomes were extracted and included in a descriptive summary. Results Nine studies consisting of 246 participants were included in our review. The overall quality of the included studies was fair. The age of the participants ranged from 61 to 78 years. In all 9 studies, more male patients had been enrolled than female patients. Overall, a proportion of patients in all the studies reported a desired major response to a danazol dose of 400 to 800 mg/day. Few studies did not observe any improvement in the platelet count. Elevated liver enzyme levels, weight gain, headache, dermatitis, and weakness were the most common AEs observed. One study reported a fatal intracerebral hemorrhage in 1 participant. Conclusions Danazol has been effective in increasing platelet count and hemoglobin level. Despite a few AEs, danazol is a safe drug for the treatment of patients with myelodysplastic syndromes.","PeriodicalId":51147,"journal":{"name":"Oncology-New York","volume":"37 12","pages":"480-487"},"PeriodicalIF":0.0,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138832860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0